The biosynthetic pathways of arphamenines A and B'.ere studied. Arphamenine A was derived from acetic acid, L-arginine and L-phenylalanine, and arphamenine B from acetic acid, L-arginine and L-tyrosine.
As reported in our previous papers=, ', two potent arninopeptidase B inhibitors, arphamenines A and B were found in the culture filtrates of CI,romobacteriu,n violaceum BMG361-CF4.
Their structures were determined to be 5-amino-
8-guarvidino-4-oxo-2-phenyl mmethyl octanoic acid (A) and 5-amino-8-guanidino-2-(4-hydroxyphenylmethyl)-4-oxo-octanoic acid (B), respectively.
To study the biosynthetic precursors of these compounds , "C-labeled acetate, L-arginine, Lphenylalanine and L-tyrosine were chosen for the radiolabeling experiments as they promoted production of arphamenines3". The role of acetate as the source of the methylene ketone moiety (-CH-CO in arphamenines was examined, using sodium [1-13C]**acetate, sodium [2-"C]*acetate or sodium [1,2-13C]acetate. Assay of Anti-aminopeptidase B Activity Inhibition of aminopeptidase B activity of rat liver by arphamenines was determined as reported previously4).
Materials and Methods

Isotope-labeled Compounds
Incorporation of Radioactivity into Arphamenines Cells of C. riolaceum BMG361-CF4 previously grown on KRAINSKY's asparagine glucose agar slants were incubated in 110 ml of a medium consisting of 3 % soluble starch , 0.5 % Prorich (Ajinomoto Co.), 1.2 % corn gluten meal and 0.2 °o CaCO3, in a 500-ml Erlenmeyer flask for 20 hours at 27°C on a rotary shaker (180 rpm). After inoculation of 0.5 ml of the seed culture thus prepared into the same medium (110 ml, =1 L-phenylalanine), the incubation was carried out as before. "C-Labeled compounds at 10 uCi (except DL- [1-14C] arginine, 20 yCi) were added at the times indicated in Table I and the biosynthetic experiments were continued for 4 hours. Labeled compounds Twenty ml of culture filtrate were chromatographed on a column of CM-Sephadex C-25 (20 ml) which was developed with 0.5 M NaCI. Fractions containing arphamenines were combined (25 ml). Five-tenth ml of the combined solution was applied to a TLC plate of silica gel (E. Merck, Art5721) and developed with the solvent system: butanol -acetic acid -water (4: 1: 1) or chloroform -methanolacetic acid -water (10: 4: 1 : 1). Arphamenines were visualized with 0.4 % solution of ninhydrin in acetone. The area containing the arphamenines was cut out from the plate and transferred to vials for counting. Eight ml of scintillation cocktail (Aquasol-2, New England Nuclear, U.S.A.) were added and the radioactivity of each sample was measured in a Beckman LS9800 liquid scintillation counter.
Preparation of 13C-Labeled Arphamenine A After strain BMG361-CF4 was cultured in 110 ml of the L-phenylalanine-containing medium for 15 hours, 50 mg of sodium [1-13C] acetate, sodium [2-13C]acetate or sodium [1,2-13C]acetate plus 100 mg of unlabeled sodium acetate and 110 mg of L-arginine monohydrochloride were added. The incubation was continued for 4 hours.
One hundred ml of culture filtrate was chromatographed on a column of CM-Sephadex C-25 (100 ml) which was developed with a linear gradient of NaCI from 0 to 0.5 M. Arphamenine A-containing fractions were combined and desalted on an Amberlite XAD-4 adsorption column; elution was carried out with 50% aqueous acetone. The crude arphamenine A thus obtained was rechromatographed on CM-Sephadex C-25 using 0.2 M NaCI as eluant. The purified arphamenine A-containing fractions were subsequently desalted on a column of Sephadex LH-20: elution of 13C-labeled arphamenine A (10 -20 mg) was attained with water.
73C NMR Spectrometry
Fourier-transform 13C NMR spectra were obtained on a Jeol FX-200 NMR spectrometer operating at 50.1 MHz. Each sample was dissolved in 0.25 ml of D2O and was run in a tube with 5 mm diameter at 25°C. The running conditions were as follows: spectral width: 15 KHz, pulse width: 2. Results and Discussion C. violaceum BMG361-CF4 produced only arphamenine A in a L-Phe-containing medium; production occurred at 15 hours as shown in Fig. 1 . By contrast, in the same medium without L-phenylalanine, In DSO (internal dioxane b 67 .4). *2 Multiplicities in the off-resonance decoupling: s , singlet; d, doublet; t, triplet. *3 Intensity of each peak in the labeled arphamenine A devided by that of the corresponding peak in the unlabeled arphamenine A, normalized to give a ratio of 1.00 for the peak of 2'-C. Thus, 14C-labeled compounds were added to the respective media at 8 and 15 hours.
As shown in Table 1 These experimental results indicated that the N-terminal moiety of arphamenines A and B was derived from L-arginine, the C-terminal moiety was derived from L-phenylalanine (arphamenine A) and 4 3 L-tyrosine (arphamenine B) and the methylene ketone (-CO-CH,-) moiety was derived from acetate.
In order to establish the distribution of radiocarbon from acetate, 13C-labeled arphamenine A was prepared with sodium [1-13C] In a subsequent paper, we will report on the complete biosynthetic pathway to arphamenines5'.
